11.19.10
Baxter has entered into a definitive agreement to acquire all of the hemophilia-related assets of Archemix, a privately-held biopharmaceutical company. The two companies have also entered into an exclusive license agreement for certain related assets.
Archemix’s lead product ARC19499, is a synthetic, subcutaneously-administered hemophilia therapy currently in a Phase I trial. ARC19499 works by blocking Tissue Factor Pathway Inhibitor (TFPI) activity to increase and improve blood clotting, potentially reducing replacement factor therapy for patients with hemophilia A and B.
“Baxter is committed to optimizing hemophilia care and improving the lives of people living with hemophilia around the world,” said Hartmut Ehrlich, M.D., vice president, global research and development and medical affairs, for Baxter’s BioScience business. “This anti-TFPI program is an important addition to other Baxter hemophilia development programs focusing on longer-acting rFVIII and rFIX and non-intravenous therapies.”
Baxter expects to record a pre-tax in-process R&D charge of approximately $30 million in 4Q10 relating to an upfront payment associated with the transaction. Archemix will also be eligible to receive milestone-related payments of as much as $285 million. Subject to regulatory approvals and other conditions, the transaction is expected to close by year-end.
Archemix’s lead product ARC19499, is a synthetic, subcutaneously-administered hemophilia therapy currently in a Phase I trial. ARC19499 works by blocking Tissue Factor Pathway Inhibitor (TFPI) activity to increase and improve blood clotting, potentially reducing replacement factor therapy for patients with hemophilia A and B.
“Baxter is committed to optimizing hemophilia care and improving the lives of people living with hemophilia around the world,” said Hartmut Ehrlich, M.D., vice president, global research and development and medical affairs, for Baxter’s BioScience business. “This anti-TFPI program is an important addition to other Baxter hemophilia development programs focusing on longer-acting rFVIII and rFIX and non-intravenous therapies.”
Baxter expects to record a pre-tax in-process R&D charge of approximately $30 million in 4Q10 relating to an upfront payment associated with the transaction. Archemix will also be eligible to receive milestone-related payments of as much as $285 million. Subject to regulatory approvals and other conditions, the transaction is expected to close by year-end.